Sharon Marsh

Summary

Publications

  1. doi request reprint Pharmacokinetics and pharmacogenomics in breast cancer chemotherapy
    Sharon Marsh
    Genome Quebec and Montreal Heart Institute Pharmacogenomics Centre, Montreal, Quebec, Canada
    Adv Drug Deliv Rev 61:381-7. 2009
  2. doi request reprint The increasing complexity of mercaptopurine pharmacogenomics
    S Marsh
    Genome Quebec and Montreal Heart Institute Pharmacogenomics Centre, Montreal, Quebec, Canada
    Clin Pharmacol Ther 85:139-41. 2009
  3. doi request reprint Pharmacogenomics of taxane/platinum therapy in ovarian cancer
    Sharon Marsh
    Genome Quebec and Montreal Heart Institute Pharmacogenomics Centre, 5000 rue Belanger, Montreal, Quebec, Canada
    Int J Gynecol Cancer 19:S30-4. 2009

Detail Information

Publications3

  1. doi request reprint Pharmacokinetics and pharmacogenomics in breast cancer chemotherapy
    Sharon Marsh
    Genome Quebec and Montreal Heart Institute Pharmacogenomics Centre, Montreal, Quebec, Canada
    Adv Drug Deliv Rev 61:381-7. 2009
    ..Pharmacogenomic associations for many drugs have yet to be identified or validated in breast cancer. Further work is needed to identify markers to screen breast cancer patients prior to therapy selection...
  2. doi request reprint The increasing complexity of mercaptopurine pharmacogenomics
    S Marsh
    Genome Quebec and Montreal Heart Institute Pharmacogenomics Centre, Montreal, Quebec, Canada
    Clin Pharmacol Ther 85:139-41. 2009
    ..However, recent research has shown that genetic contribution to mercaptopurine toxicity is more complex, possibly involving other genes, in particular ITPA, which encodes inosine triphosphate pyrophosphatase...
  3. doi request reprint Pharmacogenomics of taxane/platinum therapy in ovarian cancer
    Sharon Marsh
    Genome Quebec and Montreal Heart Institute Pharmacogenomics Centre, 5000 rue Belanger, Montreal, Quebec, Canada
    Int J Gynecol Cancer 19:S30-4. 2009
    ..The identification of pharmacogenomic markers to identify patients unlikely to respond or at risk for severe toxicity will assist in the goal of individualizing ovarian cancer treatment...